Equities research analysts expect that Lipocine Inc. (NASDAQ:LPCN) will post earnings per share (EPS) of ($0.05) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Lipocine’s earnings, with estimates ranging from ($0.06) to ($0.04). Lipocine reported earnings of ($0.06) per share in the same quarter last year, which would suggest a positive year over year growth rate of 16.7%. The business is scheduled to announce its next earnings results on Thursday, March 10th.
According to Zacks, analysts expect that Lipocine will report full year earnings of ($0.16) per share for the current year, with EPS estimates ranging from ($0.21) to ($0.08). For the next financial year, analysts expect that the firm will report earnings of ($0.12) per share, with EPS estimates ranging from ($0.17) to ($0.06). Zacks’ earnings per share averages are an average based on a survey of research analysts that that provide coverage for Lipocine.
Lipocine (NASDAQ:LPCN) last issued its earnings results on Wednesday, November 10th. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.01.
NASDAQ LPCN traded up $0.06 on Thursday, reaching $1.17. The company had a trading volume of 550,658 shares, compared to its average volume of 2,079,388. The stock has a market capitalization of $103.30 million, a P/E ratio of -5.57 and a beta of 0.39. The company’s fifty day moving average is $1.11 and its 200 day moving average is $1.25. Lipocine has a 52-week low of $0.98 and a 52-week high of $2.42.
In other Lipocine news, CEO Mahesh V. Patel acquired 25,000 shares of the business’s stock in a transaction dated Thursday, November 18th. The stock was bought at an average price of $1.09 per share, with a total value of $27,250.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 4.90% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. GSA Capital Partners LLP increased its stake in shares of Lipocine by 12.3% in the 2nd quarter. GSA Capital Partners LLP now owns 141,521 shares of the specialty pharmaceutical company’s stock worth $198,000 after acquiring an additional 15,528 shares in the last quarter. Barclays PLC increased its stake in shares of Lipocine by 243.3% in the 3rd quarter. Barclays PLC now owns 24,075 shares of the specialty pharmaceutical company’s stock worth $26,000 after acquiring an additional 17,062 shares in the last quarter. LPL Financial LLC increased its stake in shares of Lipocine by 46.8% in the 2nd quarter. LPL Financial LLC now owns 62,750 shares of the specialty pharmaceutical company’s stock worth $88,000 after acquiring an additional 20,000 shares in the last quarter. Mercer Global Advisors Inc. ADV increased its stake in shares of Lipocine by 6.8% in the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 313,111 shares of the specialty pharmaceutical company’s stock worth $341,000 after acquiring an additional 20,000 shares in the last quarter. Finally, Principal Financial Group Inc. bought a new stake in Lipocine during the 2nd quarter valued at about $29,000. Institutional investors and hedge funds own 10.54% of the company’s stock.
Lipocine Company Profile
Lipocine, Inc is a clinical-stage biopharmaceutical company, which engages in the research and development for the delivery of drugs using proprietary delivery technology. The firm involves in applying oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.